Related Experiment Video
Updated: Feb 5, 2026

Estimating Bilateral Atrial Function by Cardiovascular Magnetic Resonance Feature Tracking in Patients with Paroxysmal Atrial Fibrillation
Published on: July 20, 2022
Patient-Reported Treatment Satisfaction with Dabigatran versus Warfarin in Patients with Non-Valvular Atrial
Yan-Ping Geng1,2, Di-Hui Lan3, Nian Liu1
1Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, National Clinical Research Center for Cardiovascular Diseases, Beijing, China.
Insights
In China, dabigatran for non-valvular atrial fibrillation (NVAF) patients showed no improved satisfaction over warfarin. Higher costs and discontinuation rates were observed with dabigatran, impacting treatment adherence.
Area of Science:
- Cardiology
- Pharmacology
- Health Economics
Background:
- Patient satisfaction with anticoagulant therapy is crucial for adherence and outcomes in atrial fibrillation.
- Warfarin has known disadvantages, leading to the exploration of novel oral anticoagulants like dabigatran.
Purpose of the Study:
- To compare patient-reported treatment satisfaction between dabigatran and warfarin in Chinese non-valvular atrial fibrillation (NVAF) patients.
- To assess the impact of economic factors and discontinuation rates on treatment choice.
Main Methods:
- Patient satisfaction was measured using the Anti-Clot Treatment Scale (ACTS) questionnaire.
- Propensity score matching was used to create comparable groups of 182 dabigatran and warfarin users.
- Logistic regression analysis identified factors associated with treatment non-persistence.
Main Results:
- Global ACTS Burdens and Benefits scores were similar between dabigatran and warfarin groups.
- Dabigatran was significantly more expensive than warfarin due to lack of insurance coverage.
- Dabigatran had a higher discontinuation rate (33.5% vs. 19.2%) and greater odds of non-persistence.
Conclusions:
- Dabigatran therapy in Chinese NVAF patients did not improve satisfaction compared to warfarin.
- Increased economic burden associated with dabigatran led to higher discontinuation rates.
- Warfarin remains a viable option, considering cost-effectiveness and adherence in this population.
Background:
Anti-coagulant therapy satisfaction for patients with atrial fibrillation is a critical issue, which impacts on their treatment adherence and clinical outcomes. The disadvantages of long-term warfarin treatment are well-described, and novel oral anti-coagulants have become an alternative option.
Materials And Methods:
We compared patient-reported treatment satisfaction with dabigatran versus warfarin in non-valvular atrial fibrillation (NVAF) patients in China. Treatment satisfaction was assessed using the Anti-Clot Treatment Scale (ACTS) questionnaire, which included a 12-item ACTS Burdens scale and a 3-item ACTS Benefits scale.
Results:
Among 834 patients, 246 patients (29.5%) were taking dabigatran and the others were on warfarin. Propensity score matching was employed to identify 182 patient pairs with balanced baseline characteristics. The global ACTS Burdens score and the global ACTS Benefits score were comparable between the dabigatran and warfarin groups (44.86 ± 3.95 vs. 44.28 ± 3.51, p = 0.423; 11.49 ± 2.92 vs. 11.42 ± 3.03, p = 0.194, respectively). The monthly cost of dabigatran was significantly higher compared with that of warfarin due to a lack of insurance coverage (USD 176.78 ± 9.15 vs. USD 2.49 ± 0.76, p = 0.000). The discontinuation rate of dabigatran was significantly higher than warfarin at the 6-month follow-up (33.5% vs. 19.2%, p = 0.003). Adjusted logistic regression showed that dabigatran was associated with a significant greater odds of non-persistence (odds ratio: 2.13, 95% confidence interval: 1.27-3.59, p = 0.004).
Conclusion:
Dabigatran therapy in patients with NVAF in China associated with no improvement in satisfaction and a higher discontinuation rate compared with warfarin therapy largely due to increased economic burden.
Related Concept Videos
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Patient-centered Care
Data Reporting and Recording
Drug Dosing: Geriatric Patients
Drug Dosing: Obese Patients
Pharmacodynamics in Geriatric Patients: Effects of Age

